Fresenius Medical Care AG & Co. KGaA (FMEN) Stock Price & Analysis
FMEN Stock Chart & Stats
- Day’s Range
- MXN 822.02 - MXN 822.02
- 52-Week Range
- MXN 700.00 - MXN 900.00
- Previous Close
- MXN 822.02
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- MXN 232.58B
- Enterprise Value
- MXN 21.16B
- Total Cash (Recent Filing)
- MXN 1.48B
- Total Debt (Recent Filing)
- MXN 10.89B
- Price to Earnings (P/E)
- 14.1
- Beta
- 0.01
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 21.12
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.84%
Bulls Say, Bears Say
Bulls Say
Recurring Integrated Business Model
Frequent dialysis treatments and recurring consumables create a durable revenue base tied to patient volumes and treatment counts. FME’s combination of care delivery and product supply also links two complementary businesses, supporting customer continuity and operational scale over multiple quarters.
Revenue And Operating Recovery
The strong revenue rebound alongside improved operating and EBITDA margins indicates meaningful recovery in the core business rather than growth dependent only on financial engineering. If maintained, better operating performance can strengthen reinvestment capacity and improve earnings resilience over the next several quarters.
Strong Cash Generation
Substantial operating and free cash flow gives FME internal funding capacity for operations, investment, and balance-sheet needs. The 57.4% FCF increase is especially supportive because it shows that improving financial performance is translating into cash, not merely reported operating profit.
Bears Say
Modest Net Profitability
Despite stronger operating results, only a modest share of revenue reaches the bottom line, and net margin remains below the prior 2025 level. This limits earnings conversion and leaves profitability sensitive to costs below operating income, including interest, taxes, and other items.
Reduced Balance-Sheet Cushion
Meaningful leverage combined with a declining equity base reduces the cushion available to absorb operational setbacks or fund expansion. Although debt is described as manageable and relatively stable, the thinner equity position can constrain financial flexibility and make durable improvement more dependent on continued cash generation.
Kidney-Care Policy Competition Risk
The proposed policy direction could structurally reshape dialysis economics by encouraging earlier kidney-disease detection, preventive care, and greater competition. For a major dialysis provider, these priorities may pressure long-term late-stage treatment volumes or pricing power even as they create incentives for innovation.
Fresenius Medical Care AG & Co. KGaA News
FMEN FAQ
What was Fresenius Medical Care AG & Co. KGaA’s price range in the past 12 months?
What is Fresenius Medical Care AG & Co. KGaA’s market cap?
When is Fresenius Medical Care AG & Co. KGaA’s upcoming earnings report date?
How were Fresenius Medical Care AG & Co. KGaA’s earnings last quarter?
Is Fresenius Medical Care AG & Co. KGaA overvalued?
Does Fresenius Medical Care AG & Co. KGaA pay dividends?
What is Fresenius Medical Care AG & Co. KGaA’s EPS estimate?
How many shares outstanding does Fresenius Medical Care AG & Co. KGaA have?
What happened to Fresenius Medical Care AG & Co. KGaA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fresenius Medical Care AG & Co. KGaA?
What is the TipRanks Smart Score and how is it calculated?
Fresenius Medical Care AG & Co. KGaA Stock Smart Score
Company Description
Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG & Co. KGaA operates as a premier international provider of comprehensive dialysis services and related care, with a significant presence in Germany, North America, and numerous other countries. The company delivers essential dialysis treatments, laboratory analyses, and diagnostic services through its extensive network of outpatient dialysis clinics. Complementing its clinical offerings, Fresenius provides necessary materials, patient training, ongoing clinical monitoring, follow-up support, and arranges for the delivery of supplies directly to patients' residences. In the United States, Fresenius extends its services to hospitals, offering contract dialysis care for inpatients suffering from end-stage renal disease (ESRD) and those experiencing acute kidney failure. Beyond services, the company is a key player in the development, manufacturing, and global distribution of a broad spectrum of dialysis products. This portfolio includes items such as polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, specialized solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, Fresenius produces non-dialysis products, including those for acute cardiopulmonary conditions and apheresis. The company further enhances its offerings by developing, acquiring, and in-licensing renal pharmaceuticals, ensuring these medications and other vital supplies reach patients at home or in dialysis clinics. It also provides an array of specialized medical services, covering vascular, cardiovascular, and endovascular care, operating vascular care ambulatory surgery centers, and delivering physician nephrology and cardiology services. Fresenius Medical Care distributes its extensive product range to dialysis clinics, hospitals, and specialized treatment centers via multiple avenues, including direct sales, dedicated local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, the company managed an impressive 4,171 outpatient dialysis clinics across approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was established in 1996 and is headquartered in Bad Homburg, Germany.
- Sector
- General
- Industry
- Medical - Care Facilities
- CEO
- Shervin J. Korangy
- Employees
- 107,226
- Website
- www.freseniusmedicalcare.com
- Address
- Else-KrOener Strasse 1, Bad Homburg, HE, 61352, DE
Fresenius Medical Care AG & Co. KGaA (FMEN) Earnings & Revenues
FMEN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 3 |
| Technical Analysis | 3 | 2 | 2 |
| Moving Averages | 11 | 0 | 1 |
